1. Home
  2. TGLS vs NKTR Comparison

TGLS vs NKTR Comparison

Compare TGLS & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$41.87

Market Cap

1.9B

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$73.15

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
NKTR
Founded
1984
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.2B
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
TGLS
NKTR
Price
$41.87
$73.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$63.33
$146.67
AVG Volume (30 Days)
251.6K
629.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
1.41%
N/A
EPS Growth
N/A
N/A
EPS
1.27
N/A
Revenue
$370,984,000.00
$307,711,000.00
Revenue This Year
$13.56
N/A
Revenue Next Year
$9.04
N/A
P/E Ratio
$33.17
N/A
Revenue Growth
17.98
86.00
52 Week Low
$37.52
$25.35
52 Week High
$74.57
$109.00

Technical Indicators

Market Signals
Indicator
TGLS
NKTR
Relative Strength Index (RSI) 42.62 55.50
Support Level $41.54 $64.28
Resistance Level $47.37 $75.82
Average True Range (ATR) 2.04 2.63
MACD -0.44 0.18
Stochastic Oscillator 8.08 65.13

Price Performance

Historical Comparison
TGLS
NKTR

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: